Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
158 hedge funds and large institutions have $2.28B invested in Avidity Biosciences in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 52 increasing their positions, 51 reducing their positions, and 21 closing their positions.
250% more funds holding in top 10
Funds holding in top 10: 2 → 7 (+5)
232% more capital invested
Capital invested by funds: $687M → $2.28B (+$1.59B)
76% more call options, than puts
Call options by funds: $3.06M | Put options by funds: $1.74M
71% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 21
10% more funds holding
Funds holding: 144 → 158 (+14)
9.58% more ownership
Funds ownership: 102.45% → 112.02% (+9.6%)
2% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$52M |
| 3 |
RI
RTW Investments
New York
|
+$20.1M |
| 4 |
Janus Henderson Group
London,
|
+$19.1M |
| 5 |
O
OrbiMed
New York
|
+$15.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.84M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$7.67M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.01M |
| 5 |
Two Sigma Investments
New York
|
-$6.59M |
RNAM Hedge Fund Activity: Q1 2024 in Review
158 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q1 2024, worth a combined $2.28B — up 232% from $687M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RNAM positions and 21 closed out — a net gain of 15 holders — while 52 added to existing stakes and 51 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $60.1M. The largest seller was Balyasny Asset Management, cutting an estimated $18.3M.
- 158 institutional investors held Avidity Biosciences (RNAM) as of Q1 2024, up from 144 in Q4 2023.
- Funds reported $2.28B of Avidity Biosciences stock for Q1 2024, up 232% quarter-over-quarter.
- 36 funds opened new Avidity Biosciences positions in Q1 2024 and 21 closed out, a net change of +15 holders.
- The largest Avidity Biosciences buyer in Q1 2024 was Fidelity Investments, an estimated $60.1M added.
- The largest Avidity Biosciences seller in Q1 2024 was Balyasny Asset Management, an estimated $18.3M sold.
Based on aggregated 13F filings for Q1 2024.